Abstract:Purpose: Osteoarthritis (OA) is the most prevalent form of arthritis and its impact is increasing due to the aging population and lack of effective therapies. Currently, there are no therapeutics that modify the natural history of OA, partly because of the large gaps in our understanding of the underlying molecular and cellular mechanisms of OA. Macrophage migration inhibitory factor (MIF) is a procytokine that mediates pleiotropic inflammatory effects in selected neoplasms, and inflammatory diseases (rheumatoid arthritis and ankylosing spondylitis). However, role of MIF in OA is yet to be reported. Thus, our objective was to investigate the potential role of MIF in OA in a well-established OA cohort - the Newfoundland Osteoarthritis Study (NFOAS). Methods: The study participants were derived from the NFOAS. OA patients were all end-stage knee or hip OA patients who underwent total joint replacement surgery and controls were from the same population and had NO self-reported musculoskeletal symptoms. Two previously reported functional polymorphisms in the promoter of the MIF gene (one microsatellite -794CATT5-8 and one SNP rs755662) were genotyped by TaqMan method, and the plasma concentration of the MIF protein was measured by enzyme-linked immunosorbent assay (ELISA). Further, three other frequently studied cytokines in OA including tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-6), and interleukin-1 beta (IL-1β) were also measured in the plasma samples by ELISA. Results: A total of 232 study participants were included in the study, 119 were OA patients and 113 OA-free controls. OA patients were significantly older (65.51 ± 8.89 years vs. 58.09 ± 6.60 years), had higher BMI (32.11 ± 6.26 kg/m2 vs. 30.02 ± 4.90 kg/m2), and more males than controls (47% females vs. 62% females) (all p<0.05). The data showed that the genotypes of the two previously reported functional polymorphisms in the MIF gene were not associated with the MIF protein levels, nor associated with OA (all p>0.05). However, we found that lower MIF protein level was significantly associated with OA (4.67±2.39 ng/ml in OA vs. 7.24±4.80 ng/ml in controls; p=4.67*10-7) (Table 1). The significance remained after adjustment for age, sex, and BMI (p=2*10-6), and the association was the same for knee and hip OA. Further, we found that an increased level of all three cytokines including TNF-α, IL-6 and IL-1β was associated with OA (Table 1), which is consistent with what reported in the literature. In the multivariable analysis with logistic regression and including all four cytokines and age, sex, and BMI, we found that lower MIF protein level and higher IL-1β were independently associated with OA (all p<3.46*10-8). TNF-α and IL-6 were not significantly associated with OA in the multivariable analysis. Conclusions: Our data showed that OA patients had a significantly lower serum MIF level. A previous study also found that a lower MIF level in synovial fluid in knee OA patients compared to healthy controls. Together, these suggest that MIF might have a protective role in OA. Further, given the evidence that a higher level of MIF is associated with RA and AS, MIF may also serve as a biomarker to differentiate OA from RA and AS.

Macrophage Migration Inhibitory Factor May Play a Protective Role in Osteoarthritis